Cocrystal Pharma (NASDAQ:COCP) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Cocrystal Pharma (NASDAQ:COCP) released its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06), FiscalAI reports.

Cocrystal Pharma Trading Down 1.3%

COCP stock traded down $0.01 during trading on Thursday, reaching $1.10. 34,849 shares of the stock were exchanged, compared to its average volume of 1,029,841. The firm’s 50 day moving average is $0.99 and its 200 day moving average is $1.10. The firm has a market cap of $15.24 million, a P/E ratio of -1.51 and a beta of 1.43. Cocrystal Pharma has a twelve month low of $0.76 and a twelve month high of $2.67.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Cocrystal Pharma

An institutional investor recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.